Data demonstrate pharmacokinetic boosting activity of GS 9350.
D019380:Anti-HIV Agents / Q000008:administration & dosage; D017321:Clinical Trials, Phase I as Topic; D065692:Cytochrome P-450 CYP3A Inhibitors; D003841:Deoxycytidine / Q000008:administration & dosage / Q000031:analogs & derivatives; D004305:Dose-Response Relationship, Drug; D004338:Drug Combinations; D004347:Drug Interactions; D004359:Drug Therapy, Combination; D000069480:Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination; D004791:Enzyme Inhibitors / Q000008:administration & dosage / Q000493:pharmacokinetics* / Q000494:pharmacology; D019428:HIV Integrase Inhibitors / Q000008:administration & dosage / Q000493:pharmacokinetics*; D017320:HIV Protease Inhibitors / Q000008:administration & dosage; D006801:Humans; D009943:Organophosphorus Compounds / Q000008:administration & dosage; D015363:Quinolones / Q000008:administration & dosage / Q000493:pharmacokinetics*; D016032:Randomized Controlled Trials as Topic; D019438:Ritonavir / Q000008:administration & dosage; D016896:Treatment Outcome
D019380:Anti-HIV Agents; D065692:Cytochrome P-450 CYP3A Inhibitors; D004338:Drug Combinations; D000069480:Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination; D004791:Enzyme Inhibitors; D019428:HIV Integrase Inhibitors; D017320:HIV Protease Inhibitors; D009943:Organophosphorus Compounds; D015363:Quinolones; D003841:Deoxycytidine; C509700:elvitegravir; D019438:Ritonavir